Back to results

Factor H fragment for use as an anti-angiogenic agent

The invention relates to a complement factor H fragment for use in the therapy and/or prophylaxis of a disease involving neovascularization.
POC in vivo in a choroidal neovascularization model
Keywords: Dry AMD - neovascularization
Patent Application number: France (NP) - 30 Déc. 2015 - 15 63465
Inventors:
ABACHE Toufik,DINET Virginie,JORIEUX Sylvie

Reference:

BIO14280-T1

Business Developper
contact
Anne COCHI
Business Development Manager
Patent filling date: 30-12-2015
Rare disease: No
Second indication: No

You might also be interested in

RT00571

Hybridoma producing monoclonal antibodies against

[…]

Read more
RT00572

Hybridoma producing monoclonal antibodies against

[…]

Read more
RT00573

Hybridoma producing monoclonal antibodies against

[…]

Read more
RT00642

Galectin 3ko mouse (b6.cg-lgals3tm1poi/j)

This mouse model is available at Jackson Laboratories, Strain #:006338 […]

Read more
RT00724

Pmacs(ires-cd4) plasmids with 6 different inserts

pMACS(IRES-CD4) plasmids with 6 different inserts R13I, I12I, R10I, G9I, G9I without signal peptide, […]

Read more
RT00731

Umln hpr

[…]

Read more
RT00726

Dual vsv pseudotyped replicon for standardized

[…]

Read more
RT00578

Gfp expressing mutant rats

[…]

Read more
RT00247

Anti- beta- 1,2 linked oligomannoses (candida

Rat / mouse hybrid […]

Read more
RT00656

B6bc cell line

This murine cell line is the first syngenic hormone receptor-positive cell line of C57BL/6 strain. […]

Read more
RT00733

A breast-cancer cell line expressing a bret

We have developed a MCF7-derived cell line stably co-expressing the pleckstrin homology (PH) domain […]

Read more
RT00623

Hrln (hrar alpha) cell line

HRLN were generated by transfection of cervical cancer HeLa cells with the […]

Read more